Your browser doesn't support javascript.
loading
Effects of proangiotensin-12 infused continuously over 14 days in conscious rats.
Komatsu, Yoichi; Kida, Nobuaki; Nozaki, Naomi; Kuwasako, Kenji; Nagata, Sayaka; Kitamura, Kazuo; Kato, Johji.
Afiliación
  • Komatsu Y; Department of Nutrition Science, Minami Kyusyu University, Miyazaki 880-0032, Japan.
Eur J Pharmacol ; 683(1-3): 186-9, 2012 May 15.
Article en En | MEDLINE | ID: mdl-22414812
The carboxyl terminal-extended form of angiotensin I, proangotensin-12, was recently identified in rat tissues including the small intestine, cardiac ventricles, and kidneys. Single administration of proangiotensin-12 exerts vasoconstrictor and pressor effects, probably by conversion to angiotensin II; however, there are currently no data available about the subacute effects of proangiotensin-12. In the present study, we examined the effects of prolonged infusion of proangiotensin-12 in conscious rats. Continuous, subcutaneous infusion of 240 pmol/kg/min of proangiotensin-12 gradually elevated blood pressure over 14 days, as did the same dose of angiotensin II. The pressor effects of proangiotensin-12 were abolished by oral administration of losartan, an angiotensin II type 1 receptor blocker, or perindopril, an angiotensin converting enzyme (ACE) inhibitor. Meanwhile, angiotensin II-induced elevation of blood pressure was inhibited by losartan but not by perindopril. Both the plasma aldosterone level and heart weight/body weight ratio were increased by the prolonged infusion of proangiotensin-12, but these increases were attenuated by losartan and perindopril. The present results suggest that proangiotensin-12 infused continuously over 14 days exerts pressor effects accompanied with the elevation of plasma aldosterone and cardiac hypertrophy in an ACE- and angiotensin II type 1 receptor-dependent manner.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Fragmentos de Péptidos / Vasoconstrictores / Angiotensinógeno / Cardiomegalia / Hipertensión Límite: Animals Idioma: En Revista: Eur J Pharmacol Año: 2012 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_doencas_nao_transmissiveis Asunto principal: Fragmentos de Péptidos / Vasoconstrictores / Angiotensinógeno / Cardiomegalia / Hipertensión Límite: Animals Idioma: En Revista: Eur J Pharmacol Año: 2012 Tipo del documento: Article País de afiliación: Japón
...